Header Logo

Connection

Francesca CONRADIE to Humans

Back to Details
This is a "connection" page, showing publications Francesca CONRADIE has written about Humans.
Francesca CONRADIE
Connection Strength
1,133
Humans
  1. Validation of a Handheld 6-Lead Device for QT Interval Monitoring in Resource-Limited Settings. JAMA Netw Open. 2024 Jun 03; 7(6):e2415576.
    View in: PubMed
    Score: 0,070
  2. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022 09 01; 387(9):810-823.
    View in: PubMed
    Score: 0,062
  3. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. Reply. N Engl J Med. 2020 06 11; 382(24):2377.
    View in: PubMed
    Score: 0,053
  4. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020 03 05; 382(10):893-902.
    View in: PubMed
    Score: 0,052
  5. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes. J Acquir Immune Defic Syndr. 2019 01 01; 80(1):73-78.
    View in: PubMed
    Score: 0,048
  6. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018 12; 52(6).
    View in: PubMed
    Score: 0,048
  7. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018 09; 6(9):699-706.
    View in: PubMed
    Score: 0,046
  8. Tuberculosis control. Lancet. 2016 Mar 19; 387(10024):1157-8.
    View in: PubMed
    Score: 0,040
  9. Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB. S Afr Med J. 2013 Oct 11; 104(1):24-6.
    View in: PubMed
    Score: 0,033
  10. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
    View in: PubMed
    Score: 0,029
  11. Development and validation of an LC-MS/MS multiplex assay for the quantification of bedaquiline, n-desmethyl bedaquiline, linezolid, levofloxacin, and clofazimine in dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Feb 01; 1252:124470.
    View in: PubMed
    Score: 0,018
  12. Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis. N Engl J Med. 2024 Dec 19; 391(24):2315-2326.
    View in: PubMed
    Score: 0,018
  13. Risk factors for and timing of presumptive recurrent TB. Int J Tuberc Lung Dis. 2024 Nov 01; 28(11):527-533.
    View in: PubMed
    Score: 0,018
  14. Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
    View in: PubMed
    Score: 0,018
  15. Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Lancet Respir Med. 2024 Dec; 12(12):975-987.
    View in: PubMed
    Score: 0,018
  16. Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
    View in: PubMed
    Score: 0,017
  17. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
    View in: PubMed
    Score: 0,017
  18. Validation and application of an online extraction and liquid chromatography tandem mass spectrometry assay for the analysis of delamanid and its DM-6705 metabolite in human breast milk. J Pharm Biomed Anal. 2024 Aug 15; 246:116225.
    View in: PubMed
    Score: 0,017
  19. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS. 2004 Apr 30; 18(7):1084-5.
    View in: PubMed
    Score: 0,017
  20. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023 04; 23(4):e122-e137.
    View in: PubMed
    Score: 0,016
  21. A cohort study of post-COVID-19 condition across the Beta, Delta, and Omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participants. Int J Infect Dis. 2023 Mar; 128:102-111.
    View in: PubMed
    Score: 0,016
  22. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet. 2022 11 26; 400(10366):1858-1868.
    View in: PubMed
    Score: 0,016
  23. Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health. 2022 09; 10(9):e1247-e1256.
    View in: PubMed
    Score: 0,015
  24. Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022 May 30; 74(10):1736-1747.
    View in: PubMed
    Score: 0,015
  25. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. BMJ Open. 2021 12 03; 11(12):e051521.
    View in: PubMed
    Score: 0,015
  26. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis. 2022 04; 22(4):496-506.
    View in: PubMed
    Score: 0,015
  27. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2022 02; 22(2):242-249.
    View in: PubMed
    Score: 0,015
  28. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021 07; 21(7):975-983.
    View in: PubMed
    Score: 0,014
  29. Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis? Eur Respir J. 2020 07; 56(1).
    View in: PubMed
    Score: 0,013
  30. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J. 2020 03; 55(3).
    View in: PubMed
    Score: 0,013
  31. Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study. Clin Infect Dis. 2020 01 16; 70(3):436-445.
    View in: PubMed
    Score: 0,013
  32. Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. Clin Infect Dis. 2020 01 16; 70(3):425-435.
    View in: PubMed
    Score: 0,013
  33. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019 12; 7(12):1048-1058.
    View in: PubMed
    Score: 0,013
  34. HIV and Solid Organ Transplantation: Where Are we Now. Curr HIV/AIDS Rep. 2019 10; 16(5):404-413.
    View in: PubMed
    Score: 0,013
  35. Needs must: living donor liver transplantation from an HIV-positive mother to her HIV-negative child in Johannesburg, South Africa. J Med Ethics. 2019 05; 45(5):287-290.
    View in: PubMed
    Score: 0,012
  36. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019 03 28; 380(13):1201-1213.
    View in: PubMed
    Score: 0,012
  37. Multidrug-resistant tuberculosis outbreak in South Africa. Lancet Infect Dis. 2019 02; 19(2):134-135.
    View in: PubMed
    Score: 0,012
  38. Frequency of Circulating CD4+Ki67+HLA-DR- T Regulatory Cells Prior to Treatment for Multidrug Resistant Tuberculosis Can Differentiate the Severity of Disease and Predict Time to Culture Conversion. Front Immunol. 2018; 9:2438.
    View in: PubMed
    Score: 0,012
  39. Living donor liver transplant from an HIV-positive mother to her HIV-negative child: opening up new therapeutic options. AIDS. 2018 10 23; 32(16):F13-F19.
    View in: PubMed
    Score: 0,012
  40. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Appl Health Econ Health Policy. 2018 Feb; 16(1):43-54.
    View in: PubMed
    Score: 0,011
  41. Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa. Int J Tuberc Lung Dis. 2017 10 01; 21(10):1106-1111.
    View in: PubMed
    Score: 0,011
  42. A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis. PLoS One. 2017; 12(5):e0176660.
    View in: PubMed
    Score: 0,011
  43. The epidemiology and clinical features of paraffin (kerosene) poisoning in rural African children. Ann Trop Paediatr. 1997 Mar; 17(1):49-55.
    View in: PubMed
    Score: 0,011
  44. Turning the tide against tuberculosis. Int J Infect Dis. 2017 Mar; 56:6-9.
    View in: PubMed
    Score: 0,011
  45. Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa. Trop Med Int Health. 2017 02; 22(2):241-251.
    View in: PubMed
    Score: 0,010
  46. Cutting the cost of South African antiretroviral therapy using newer, safer drugs. S Afr Med J. 2016 Dec 21; 107(1):28-30.
    View in: PubMed
    Score: 0,010
  47. A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis. S Afr Med J. 2016 Mar 17; 106(4):30-1.
    View in: PubMed
    Score: 0,010
  48. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother. 2016 Apr; 71(4):1037-40.
    View in: PubMed
    Score: 0,010
  49. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016 Feb; 47(2):564-74.
    View in: PubMed
    Score: 0,010
  50. A subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversion. PLoS One. 2014; 9(7):e102178.
    View in: PubMed
    Score: 0,009
  51. Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection. PLoS One. 2014; 9(2):e89925.
    View in: PubMed
    Score: 0,009
  52. Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy. AIDS Res Hum Retroviruses. 2013 Oct; 29(10):1287-92.
    View in: PubMed
    Score: 0,008
  53. Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network. Clin Infect Dis. 2012 May; 54 Suppl 4:S261-5.
    View in: PubMed
    Score: 0,008
  54. The medical proof doesn't get much better than VMMC. S Afr Med J. 2012 Feb 23; 102(3 Pt 1):124-5; discussion 125-6.
    View in: PubMed
    Score: 0,007
  55. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
    View in: PubMed
    Score: 0,007
  56. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011 Oct; 11(10):750-9.
    View in: PubMed
    Score: 0,007
  57. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS. 2011 Feb 20; 25(4):479-92.
    View in: PubMed
    Score: 0,007
  58. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
    View in: PubMed
    Score: 0,007
  59. Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2012 Feb; 41(1):43-54.
    View in: PubMed
    Score: 0,007
  60. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1499-509.
    View in: PubMed
    Score: 0,007
  61. Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J. 2010 Sep 07; 100(9):566, 568, 570-1.
    View in: PubMed
    Score: 0,007
  62. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
    View in: PubMed
    Score: 0,007
  63. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40.
    View in: PubMed
    Score: 0,007
  64. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009 Jun 01; 48(11):1617-23.
    View in: PubMed
    Score: 0,006
  65. Integration of antiretroviral treatment within antenatal care in Gauteng Province, South Africa. J Acquir Immune Defic Syndr. 2006 Dec 15; 43(5):577-81.
    View in: PubMed
    Score: 0,005
  66. Studies in metabolism of zinc. Part I. Serum-zinc levels in outwardly healthy adults, white and Bantu. S Afr J Lab Clin Med. 1960 Mar; 6:29-36.
    View in: PubMed
    Score: 0,001
  67. Serum; copper levels of the South African Bantu. S Afr J Lab Clin Med. 1958 Dec; 4(4):294-8.
    View in: PubMed
    Score: 0,001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.